In November 2023, the UK became the first country in the world to authorise a Crispr gene-editing therapy.

Researchers identified AlCas12a, a compact, versatile enzyme that improves CRISPR gene editing and enables faster molecular ...

Food made from pigs engineered to be resistant to a porcine virus are as safe and nutritious to eat as pork currently on the ...

Scientists have uncovered a 400-million-year-old genetic secret that gave spiders the ability to produce silk and weave their ...

Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 ...

Some scientists who argue for deregulation deny outdoor gene editing is possible. But patents and the scientific literature tell a very different story. Report: Claire Robinson ...

Life-changing research is underway at Kansas State University that could change the way people with celiac disease enjoy ...

While the clinical hold has been lifted on the MAGNITUDE-2 trial, it remains in place on the MAGNITUDE study.

Spanish researchers discover AlCas12a, a groundbreaking enzyme for next-generation gene editing.The protein, discovered in wastewater, is smaller, ...

Despite decades of reform and strong public research institutions, Bangladesh’s seed system continues to fall short of meeting farmers’ needs. Structural gaps in access, affordability, and climate res ...

Pneumocystis is an unwieldy genus of fungal pathogens that cause severe pneumonia, particularly in immunocompromised people like those with HIV/AIDs or who have received organ transplants. However, ...

The FDA has lifted a clinical hold on Intellia Therapeutics’ Magnitude-2 phase 3 trial of nexiguran ziclumeran, or nex-z: a CRISPR-based gene therapy for patients with hereditary transthyretin ...